Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect - Test2 - elhamkhani - TriplyDB

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

http://www.wikidata.org/entity/Q28293218

about

Novel NMDA receptor modulators: an update Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.Diagnosing pseudobulbar affect in traumatic brain injury.Pseudobulbar affect: an under-recognized and under-treated neurological disorder.Pseudobulbar affect: burden of illness in the USA.Pseudobulbar affect: prevalence and management.Multidisciplinary Interventions in Motor Neuron Disease.New considerations in the design of clinical trials for amyotrophic lateral sclerosis PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.Dextromethorphan/quinidine: in pseudobulbar affect.Current concepts in the pharmacotherapy of pseudobulbar affect.EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.A systematic review of pharmacological pain management in multiple sclerosis.Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment Options Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP).Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.Outcome measures in amyotrophic lateral sclerosis clinical trials Laughter, crying and sadness in ALS.Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.Introduction to supplement: the current status of treatment for ALS.Improving symptom management for people with amyotrophic lateral sclerosis.Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules.Symptom management in amyotrophic lateral sclerosis: We can do better.Management of post-stroke mood and emotional disturbances.Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).Amyotrophic lateral sclerosis

P2860

Q26849614-18140063-6E2D-48F5-97E4-5D2DFC9A6868 Q28071256-51FBCB99-2EB0-4462-83E3-1A9D27C60C25 Q30365902-0B66C0F3-8A83-4D6C-9902-A89E35369E80 Q30634431-BF87C100-2958-4507-8B5B-3C7742C73C43 Q33838839-323ADD23-3FBA-49F2-AB37-3D2B6C7BE7B9 Q34026748-4504F537-A437-48DA-BCFC-FAF68AC68477 Q34354384-FE9592B1-D7BD-459A-96C0-1396928DA87F Q34630034-2B0A7CCE-CC18-4080-AD9C-9496DECD54BF Q34641967-A0CDD2A4-B66E-49E2-B13E-8C3707C857F8 Q34658447-8A167E9B-A62C-4166-8D75-94EAB613A915 Q35623262-FCC8B0D5-57EA-4FA8-9BD6-9D0BF581E035 Q35910744-AC8540E3-5CB7-4F87-B04C-6C790AB00BE5 Q36045307-BF92E203-EA1B-43F3-98EF-86B304B959B3 Q36551001-308A1E60-333B-494C-8462-5DC93980EB8F Q37021521-6B4EBA9C-2A38-4CB4-8DA4-AAC366949375 Q37081555-C18319B3-A717-42C1-A610-4CC14EA4C8F7 Q37863094-3D072637-E7F9-42D5-A8DC-91522B45455C Q37895256-7BF2C8F3-5C34-4304-B80A-06E8E6F75B11 Q37931374-A27EB7B1-66C7-49F5-869F-EA6FACAC14FA Q38148499-25BB5B4F-F8AC-4FA3-8521-6D5DB1679653 Q38219309-854B5FDE-7F65-4D3D-BEA0-CC92484092C6 Q38219475-E4D92D2A-DF61-49EA-8EAD-EAB4106BD52E Q38270903-840ABDFE-AD0D-4F3C-BF13-BDA726FDA876 Q38401900-C1C6E527-9CA1-4013-8D6B-2D0EBD009B5B Q38676032-A8BE61A0-637F-47A1-A42A-3B0AAE66E5AC Q39530443-C60593F6-3F7A-486F-9D44-3192CC33DE18 Q41009555-B23D7555-0683-47D9-BCD0-12BD475FC0DC Q41164001-FDF26084-8D56-445C-A337-ED751CFA6E2F Q41837997-15EBA62F-3D3C-47BC-9731-0CA72A2E62D3 Q42275960-E61F1D8A-F21D-41FA-915B-8D1082D4A54C Q42318071-EEAF7FC6-C2F9-44E7-B907-240AC8EAD9F8 Q46105473-DD794D80-6E73-4982-B2A3-6A7B64F1FA49 Q46135234-D3EB5EC6-AAEF-475A-9564-40E9E7BB2BA6 Q46604820-3CDBF549-B027-49D6-A701-A0CF51CBEDB8 Q46932015-6B4E3A5F-837B-40CB-92F9-06D5CA0A6C1E Q47102766-F95A15B5-304D-4F3E-A441-F83861779233 Q47731936-26351AB5-4D66-437A-881B-66A5DF0CF24E Q55664870-792CCE76-3C2B-4EDC-88A7-C2798021FC16 Q56531747-DFCD2582-8F5C-47E4-A2BF-08DC0FE1F9D4

P2860

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

http://www.wikidata.org/entity/Q28293218

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@ast

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@en

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@nl

type

label

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@ast

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@en

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@nl

prefLabel

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@ast

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@en

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@nl

P1433

Q28293218-2A9C78C5-D647-416E-8790-B243B8A7BCCD

P1476

Q28293218-4391E083-340E-49A3-9B85-F2508E582731

P2093

Q28293218-3E662800-B9F8-4EA2-842D-D42E5BDCA1B2

Q28293218-73D9E4C5-CD7F-435B-8E3D-015CAEFB351D

Q28293218-8614BF62-B8A6-433A-AA31-DFCFC25E9ECC

Q28293218-8D3DBBAE-6F33-4852-A42A-7719A1AA9CF6

Q28293218-91F7834F-457D-4619-9C60-7ECE8189CCC2

Q28293218-CD75D724-AE3A-43FB-BEF1-0D5DD46EF8F4

Q28293218-F8D3A81B-2515-4FD5-819A-9CD9EDA922C8

Q28293218-FBD8D99E-B373-4385-A3B6-93E843771EEF

P2860

Q28293218-07A886A7-B59A-4A77-BD8B-B008F9505658

Q28293218-243F4164-979B-495E-8D16-C3FF9989C104

Q28293218-2A456059-2763-4724-874D-D8359BACEB3D

Q28293218-4D0A9AF9-DC0A-41FE-A451-648DB6E7219C

Q28293218-5BD377FA-DD50-48F8-B791-29AFCE3E0544

Q28293218-C0DCB931-CC58-4600-9F76-E62C4E94C685

Q28293218-DBC339A0-20A4-4F5E-B927-5C76047FD7EC

P304

Q28293218-1FB80FB7-E02E-4D56-84C3-1B19A91172E2

P31

Q28293218-258B41B9-C4E8-4F0E-A358-3ACFE47BF9C1

P3181

Q28293218-A6762CEB-E518-4C12-B3BC-93F81A983529

P356

Q28293218-472438EE-32C6-4D55-BF41-E422B9B2263A

P407

Q28293218-1BF72815-1AE7-439C-9136-EDD7CC0EB3AD

P433

Q28293218-FBC44FA6-4D31-4838-B333-B39FA3F85222

P478

Q28293218-61940F5B-BAD5-47F0-9AC8-F1740A6C5BD6

P577

Q28293218-CF9875D6-37DD-449A-BFA6-546FA64DA471

P5875

Q28293218-4B22E1A4-B6A8-4A47-A28D-D0599C3D2BA0

P698

Q28293218-991CE0A4-F350-40F7-9188-FEE57E5F975E

P3181

P356

P1433

Annals of Neurology

P1476

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

@en

P2093

Adrian Hepner

http://www.w3.org/2001/XMLSchema#string

Benjamin Rix Brooks

http://www.w3.org/2001/XMLSchema#string

Daniel Wynn

http://www.w3.org/2001/XMLSchema#string

Erik P Pioro

http://www.w3.org/2001/XMLSchema#string

Jeffrey Cummings

http://www.w3.org/2001/XMLSchema#string

Randall Kaye

http://www.w3.org/2001/XMLSchema#string

Randolph Schiffer

http://www.w3.org/2001/XMLSchema#string

Ronald A Thisted

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis

Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Treatment of "emotional incontinence" with levodopa.

Pathologic laughing and crying treated with levodopa.

P304

693-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

899034

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ANA.22093

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46257163

http://www.w3.org/2001/XMLSchema#string

P698

20839238

http://www.w3.org/2001/XMLSchema#string